CDT Equity Announces 1-for-25 Reverse Stock Split to Regain Nasdaq Compliance
CDT is trading near its 52-week low of $0.12 (19% below the low) on elevated volume (3.3× avg).
Summary
CDT Equity is enacting a 1-for-25 reverse stock split effective September 28, 2026, to regain compliance with Nasdaq's $1 minimum bid price rule. The stock currently trades at $0.0976, and the company faces a going concern warning with only $747K in cash.
Key Events · Corporate Governance and Compliance · CDT
-
1-for-25 Reverse Stock Split Approved
Board approved a 1-for-25 reverse split on September 24, 2026, effective September 28, 2026 at 5:00 pm ET. Trading on a split-adjusted basis begins September 29, 2026.
-
Post-Split Share Count Reduced to ~1.12M
Outstanding shares will be reduced to approximately 1,124,515 from roughly 28.1 million pre-split shares. Authorized shares remain at 250 million, leaving massive headroom for future dilution.
-
Nasdaq Compliance at Stake
The split is intended to lift the stock price above Nasdaq's $1 minimum bid requirement. At $0.0976 today, the stock would need to trade above $2.44 post-split to clear the threshold.
-
Second Reverse Split in Two Months
This follows a 1-for-10 reverse split enacted in July 2026. The prior split failed to sustain compliance, and the company remains under going concern warning with only $747K in cash as of the last 10-Q.
Analysis · CDT · Life Sciences
CDT Equity is executing a second reverse stock split in just over two months — this time 1-for-25 — after the prior 1-for-10 split in July failed to keep the stock above Nasdaq's $1 minimum bid requirement. The stock currently trades at $0.0976, far below the $1 threshold, and the company has been burning through cash with only $747K on hand as of the last 10-Q. The split will reduce outstanding shares to approximately 1,124,515, but with 250 million authorized shares and a history of highly dilutive financings, the company retains enormous capacity to issue new shares. This is a survival move to maintain the Nasdaq listing, but it does not address the underlying cash crisis or the going concern warning disclosed in prior filings.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.12 to $1,778.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.